EVAX
Evaxion AS
NASDAQ · Healthcare · Biotechnology · DK
$2.97
+0.34%Oct 30, 2026, 08:00 UTC
Evaxion A/S received the 2026 International Evaxion A/S Award for AI-Immunology as the best digital health solution.
Source:Oct 23, 2026, 06:00 UTC
Evaxion A/S announced new three-year immune and clinical outcome data for its personalized cancer vaccine EVX-01 in patients with advanced melanoma, reporting 89% vaccine target precision and sustained T-cell and clinical responses.
Source:Sep 14, 2026, 12:00 UTC
Evaxion A/S began applying its AI-Immunology platform to autoimmune diseases, expanding its therapeutic focus beyond vaccines.
Source:Aug 14, 2026, 12:00 UTC
Evaxion A/S announced it will release its second quarter 2026 financial results and provide a business update on August 20, 2026.
Jun 15, 2026, 20:05 UTC
Nyxoah SA's Genio hypoglossal nerve stimulation therapy won the Prix Galien UK 2026 Award for Best Medical Technology at a ceremony in London.
Jun 12, 2026, 07:00 UTC
Evaxion received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform.
Source: